B+
Bull case
25%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
KRMD
KORU MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Record Q2 revenue, 23.4% core growth, gross-margin improvement, positive quarterly net income, and maintained expectations for positive adjusted EBITDA support a measured operating-improvement thesis. The September 8 open-market purchase of 32,000 shares at $3.16 by reporting owner Adam Kalbermatten is an alignment signal, though not evidence of future results [#SEC-8K-2026-08-05] [#SEC-FORM4-2026-09-09].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Connected-monitoring technology may require additional development, integration, regulatory work, and customer adoption before producing material returns.
Momentum
96
Value
42
Sentiment
86
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.70 · Bull $5.00 · Bear $2.20Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum96 · Δ7d -
Value42 · Δ7d -0.1
Sentiment86 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Connected-monitoring technology may require additional development, integration, regulatory work, and customer adoption before producing material returns.
- • European conversion to pre-filled syringes could extend the anticipated moderation in international core growth.
- • International growth is expected to moderate, Pharma Services and Clinical Trials revenue declined 35% year over year, and the Phesgo filing withdrawal delays the prior oncology pathway.
Catalyst clock
2026-12-31
Execution against refined FY2026 guidance
Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
28% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.4
Sentiment
86
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 96.0 / Value 41.9 / Sentiment 85.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.70
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$155.14M
Beta
0.44
Shares Out
46.17M
P/E (TTM) · Derived
-58.8
P/S (TTM)
6.60
P/FCF (TTM) · Derived
202.41
Rev YoY
+18.2%
EPS YoY
-213.3%
Gross Margin
+60.7%
Op Margin
-3.7%
Net Debt
-$5.38M
Current Ratio
2.72
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data